EGFR and non-small cell lung carcinoma: These results suggest that the simultaneous targeting of CypA/CD147 and EGFR can more effectively suppress EGFR-mutant NSCLC CSC growth by disrupting crosstalk between the CypA/CD147 and EGFR pathways.